Corbus Pharmaceuticals Holdings (CRBP) Return on Sales (2015 - 2022)

Corbus Pharmaceuticals Holdings' Return on Sales history runs 8 years deep, the most recent figure standing at 9.81% for Q2 2022.

• On a quarterly basis, Return on Sales fell 586.0% year-over-year to 9.81% in Q2 2022; TTM through Jun 2022 was 9.81%, a 929.0% decrease from a year earlier, with the FY2021 full-year figure at 1.49%, down 124.0% from the prior year.
• Return on Sales eased to 9.81% in Q2 2022 per CRBP's latest filing, from 5.4% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2019 and bottomed at 9.81% in Q2 2022.
• The 5-year median for Return on Sales is 0.49% (2018), against an average of 1.83%.
• Across the five-year window, Return on Sales surged 88 bps in 2019 and tumbled 586 bps in 2022, its largest moves.
• Year by year, Return on Sales stood at 0.88% in 2018, then soared by 101 bps to 0.01% in 2019, then plunged by 1381 bps to 0.12% in 2020, then sank by 1471 bps to 1.91% in 2021, then sank by 412 bps to 9.81% in 2022.
• Per Business Quant, the three latest CRBP Return on Sales figures stand at 9.81% (Q2 2022), 5.4% (Q1 2022), and 1.91% (Q4 2021).